Session Ⅰ : Current status and Future direction

  • Dongho Lee, M.D.,Ph.D KPBMA
    2018 – Present : President, Korea AI Center for Drug discovery and development at KPBMA
    2016 – Present : NetVation partners Co., Founder and chairperson
    2014 – 2018 : Asan Medical Center
    Professor, Department of Clinical Pharmacology and Therapeutics
    Professor, Department of Anesthesiology and Pain Medicine
    2011 – 2014 : Korea Drug Development Fund (KDDF), Chief Executive Officer,
    2007 – 2011 : Korea National Enterprise for Clinical Trials (KoNECT), Vice President
    2007 – 2011 : Asan Medical Center,
    Executive Director, Clinical trial center
    Professor, Department of Clinical Pharmacology and Therapeutics
    Professor, Department of Anesthesiology and Pain Medicine
  • Mishal Patel AstraZeneca
    After a brief sabbatical in investment banking, Mishal returned to research at the Institute of Cancer research, in the Computational Biology and Chemogenomic group developing AI methods to predict ‘drugability’, before moving to the clinical world at the Royal Surrey County Hospital. Here, he developed a national breast screening medical imaging database and developed algorithms and systems to modernize national breast screening service by predicting high risk patients prior to cancer development. Currently, Mishal heads the healthcare and image analytics and the machine learning and visual analytics group(s) at AstraZeneca. He is a member of the UK All-Party Parliamentary Group on Artificial Intelligence.
  • Paul Kohlhaas Molecule Protocol
    Paul Kohlhaas is a technology serial entrepreneur with a passion for open source utility networks. A profound passion for biotech and pharmaceutical economics led him to found Molecule Protocol, a software network that enables biotech and pharmaceutical companies to accelerate therapeutics development in a collaborative data-driven IP marketplace. Paul Kohlhaas graduated in economics from the University of St. Gallen, Switzerland and studied computer science. After gaining experience in capital markets and management consulting he founded Linum Labs AG, a blockchain architecture studio where he helped companies such as Barclays, PwC or Deloitte build blockchain implementations in healthcare and digital identity. He also worked at ConsenSys AG as a Director of Business Development, focusing on system engineering and decentralized AI.
  • Seonee Nam SK holdings
    SK Holdings 2010-present

    General Manager, Healthcare Group
    Business development for Healthcare platform service
    Project Leader, Development of AI based Drug Design platform
    Project Leader, Development of AI based Antibiotics advisor

    Manager, Project Management Office Group
    Domestic Patent (10-17630423) “Effort Estimation System for IT Service business”
    Certified Scrum Master(CSM) for Agile Project, Scrum Alliance

Session Ⅱ : Beyond traditional computational approach

  • Dongsup Kim, Ph.D KAIST
    2003 – Present : Professor, Dept. Bio and Brain Engineering, KAIST
    2001 – 2003 : Postdoctoral Researcher, Oak Ridge National Laboratory
    1998 – 2000 : Postdoctoral Researcher, University of Pennsylvania
    Publications (Representatives)
    Lee A, Kim D, "CRDS: Consensus Reverse Docking System for Target Fishing", Bioinformatics. 2019 Aug 20.
    Jeon W, Kim D., "FP2VEC: a new molecular featurizer for learning molecular properties", Bioinformatics. 2019 May 9.
    Lee A, Hong S, Kim D., "KRDS: a web server for evaluating drug resistance mutations in kinases by molecular docking", J Cheminform. 2018 Apr 10;10(1):20.
    Lee K, Lee M, Kim D., "Utilizing random Forest QSAR models with optimized parameters for target identification and its application to target-fishing server", BMC Bioinformatics. 2017 Dec 28;18(Suppl 16):567.
    Yang D, Jang I, Choi J, Kim MS, Lee AJ, Kim H, Eom J, Kim D, Jung I, Lee B., "3DIV: A 3D-genome Interaction Viewer and database", Nucleic Acids Res., 2017 Nov 2.
    Hong S, Kim D, "Computational characterization of chromatin domain boundary-associated genomic elements.", Nucleic Acids Res. 2017 Oct 13;45(18):10403-10414.
  • Andreas Bender University of Cambridge
    Group Leader, Leiden University 2007/2008
    Group Leader, Cambridge University 2009-today
    Co-founder of companies Healx (healx.io) and Pharmenable (pharmenable.com)
    Ca 200 publications, see https://www.ch.cam.ac.uk/group/bender/publications for details
    Website: www.andreasbender.de
  • Byungchan Kim Schrödinger
    Schrödinger LLC
    Drug Discovery Principal Scientist/Modelling Lead (2016 – present)

    Schrödinger LLC
    Technical Lead of FEP+, WaterMap, and Desmond (2006 – 2016)
    “Accurate Modeling of Scaffold Hopping Transformations in Drug Discovery”
    L Wang, Y Deng, Y Wu, Byungchan Kim, DN LeBard, D Wandschneider, M Beachy,
    Journal of chemical theory and computation, 2016, 13 (1), 42-54

    “Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field”
    L Wang, Y Wu, Y Deng, Byungchan Kim, L Pierce, G Krilov, D Lupyan, S Robinson,
    Journal of the American Chemical Society, 2015, 137 (7), 2695-2703
  • Sangok Song Standigm
    Sep 2018 – present : Chief Transformation Officer, Standigm
    May 2012 – Aug 2018 : Co-founder and Chief Operating Officer, Standigm
    Mar 2012 – Apr 2015 : Senior researcher, Samsung Advanced Institute of Technology
    Aug 2009 – Feb 2012 : Research associate, University of Pittsburgh Medical Center
    Mar 2006 – Jul 2009 : Research associate, Cornell University
    Yun-Il Lee, Hojin Kang, Young Wan Ha, Ki-Young Chang, Sung-Chun Cho, Sang Ok Song, Hyein Kim, Areum Jo, Rin Khang, Jeong-Yun Choi, Yunjong Lee, Sang Chul Park, Joo-Ho Shin: Diaminodiphenyl sulfone-induced parkin ameliorates age-dependent dopaminergic neuronal loss. Neurobiology of Aging 05/2015;41:1-10

Session Ⅲ : The Practical Impact of AI in Drug Discovery So Far

  • Jaewoo Kang, Ph.D Korea University
    2006 – Present : Assistant/Associate/Full Professor, Korea University
    2003 – 2006 : Assistant Professor, North Carolina State University (NC, US)
    2000 – 2001 : CTO/Founder, WISEngine Inc. (CA, US/Seoul)
    1997 – 1998 : Technical Staff, Savera Systems (NJ, US)
    1996 – 1997 : Consultant/Senior Technical Staff, AT&T Labs Research (NJ, US)
    Publications (Representatives)
    Jinhyuk Lee, Wonjin Yoon, Sungdong Kim, Donghyeon Kim, Sunkyu Kim, Chan Ho So, Jaewoo Kang. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics (2019)
    Minji Jeon, Donghyeon Park, Jinhyuk Lee, Hwisang Jeon, Miyoung Ko, Sunkyu Kim, Yonghwa Choi, Jaewoo Kang. ReSimNet: Drug Response Similarity Prediction using Siamese Neural Networks. Bioinformatics (2019)
    Michael P Menden, Dennis Wang, Yuanfang Guan, Mike J Mason, Bence Szalai, Krishna C Bulusu, Thomas Yu, Jaewoo Kang, Minji Jeon, et al. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications 10, Article number: 2674 (2019)
  • Naheed Kurji Cyclica
    President & CEO ay Cyclica Inc. 2016-present
    Vice President Finance & CFO at Cyclica Inc. 2014-2016
    Associate Director, Corporate Finance (Diversified Industries) at Bank of Montreal 2012-2014
    Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474 (Biochemical and Biophysical Research Communications)
    Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics (Frontiers in Oncology)
    Bridging Biology, Chemistry And Computation To Design The Best Medicines (Forbes)
    The Future of Pharma: The Role Of Biotech Companies (Forbes)
  • Chaemin Lim A2A Pharmaceuticals
    2018-Current Chief Scientific Officer, A2A Pharmaceuticals Inc, New York, NY
    2014-2017 Research Fellow, University of Pittsburgh Chemical Diversity Center (UP-CDC), University of Pittsburgh, Pittsburgh, PA
    2013-2014 Research Associate, Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, South Korea
    - Drug discovery scientist with multidisciplinary background. Extensive research experience in synthetic medicinal chemistry, chemical biology, and drug discovery covering multiple therapeutic areas, including broad hands-on experience with computational tools such as molecular modeling, QSAR, cheminformatics, and ML/AI tools. Have facilitated early-stage drug discovery projects from the initial stages to preclinical development, leading to 9 patent applications as a co-inventor and 21 SCI publications.
    - At A2A Pharmaceuticals, I am responsible for overall scientific, programmatic, administrative, and financial oversight of the project to advance A2A’s pipeline and scientific platform. I work directly with and supervise A2A Pharmaceuticals personnel and fee-for-service contract research organizations (CROs) to carry out the proposed studies and analyses. I conduct research on ‘hit to lead’ development processes as well as prioritize analog synthesis and lead optimization. Additionally, I am developing A2A’s target-specific workflow using machine learning (ML) and artificial intelligence (AI) tools.
  • Woo Youn Kim KAIST
    2015 –Present : Associate Professor (tenured), Department of Chemistry, KAIST
    2011 – 2015 : Assistant Professor, Department of Chemistry, KAIST
    2009 – 2010 : Postdoctoral Fellow, Max-Planck Institute of Microstructure Physics(Halle, Germany)
    2009 : Postdoctoral Fellow, Department of Chemistry, POSTECH
    Honours and Awards
    Excellent Teaching Award, College of Natural Sciences, KAIST, 2015
    EWon Assistant Professor, 2014 – 2016
    BK21 Best Achievement Commendation from Ministry of Education, Science, and Technology, 2012
    TJ Park Science Fellow, 2011 – 2013
    Best Thesis Award, POSTECH, 2009
    Best Thesis Award, Korean Chemical Society, 2009
    Publications (Representatives)
    Jaechang Lim, Sang-Yeon Hwang, Seungsu Kim, Seokhyun Moon, and Woo Youn Kim*, Scaffold-based molecular design using graph generative model.
    Jaechang Lim, Seongok Ryu, Kyubyong Park, Yo Joong Choe, Jiyeon Ham, and Woo Youn Kim*, Predicting drug-target interaction using a novel graph neural network with 3D structure- embedded graph representation., J. Chem. Inf. Model. 59, 3981 (2019).